Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.
2.
3.
4.

h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.

Watanabe K, Tajino T, Sekiguchi M, Suzuki T.

Am J Clin Pathol. 2000 May;113(5):663-8.

PMID:
10800398
5.

Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract.

Coco DP, Hirsch MS, Hornick JL.

Am J Surg Pathol. 2009 Dec;33(12):1795-801.

PMID:
19950405
6.

h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.

Nucci MR, O'Connell JT, Huettner PC, Cviko A, Sun D, Quade BJ.

Am J Surg Pathol. 2001 Apr;25(4):455-63.

PMID:
11257619
7.

Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.

Loddenkemper C, Mechsner S, Foss HD, Dallenbach FE, Anagnostopoulos I, Ebert AD, Stein H.

Am J Surg Pathol. 2003 Nov;27(11):1458-62.

PMID:
14576480
8.

h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin.

D'Addario SF, Morgan M, Talley L, Smoller BR.

J Cutan Pathol. 2002 Aug;29(7):426-9.

PMID:
12139638
9.

Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.

Sakamoto A, Oda Y, Yamamoto H, Oshiro Y, Miyajima K, Itakura E, Tamiya S, Honda Y, Ishihara A, Iwamoto Y, Tsuneyoshi M.

Virchows Arch. 2002 Apr;440(4):404-9. Epub 2001 Nov 7.

PMID:
11956822
11.
12.

Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.

Ceballos KM, Nielsen GP, Selig MK, O'Connell JX.

Am J Clin Pathol. 2000 Nov;114(5):746-53.

PMID:
11068549
13.

Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.

Sgantzos MN, Galani V, Arvanitis LD, Charchanti A, Psathas P, Nakou M, Havaki S, Kallioras V, Marinos E, Vamvakopoulos NC, Kittas C.

Pathol Res Pract. 2007;203(1):31-7. Epub 2006 Nov 28.

PMID:
17129677
14.

Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.

Bodner-Adler B, Nather A, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K.

Gynecol Oncol. 2006 Oct;103(1):186-9. Epub 2006 Apr 3.

PMID:
16595146
15.

H-caldesmon expression in myofibroblastoma of the breast: evidence supporting the distinction from leiomyoma.

Magro G, Gurrera A, Bisceglia M.

Histopathology. 2003 Mar;42(3):233-8.

PMID:
12605642
16.

Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.

Bodner-Adler B, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K.

Gynecol Oncol. 2005 Jan;96(1):62-6.

PMID:
15589581
17.
18.

Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.

Matsuyama A, Hisaoka M, Hashimoto H.

Pathol Int. 2010 Mar;60(3):212-6. doi: 10.1111/j.1440-1827.2009.02508.x.

PMID:
20403047
19.

Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.

Gannon BR, Manduch M, Childs TJ.

Int J Gynecol Pathol. 2008 Jan;27(1):68-73.

PMID:
18156978
20.

Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma.

Martin SA, Sears DL, Sebo TJ, Lohse CM, Cheville JC.

Am J Surg Pathol. 2002 Mar;26(3):292-300.

PMID:
11859200

Supplemental Content

Support Center